A. Mullard, Regulators approve the first cancer-killing virus, Nature Reviews Drug Discovery, vol.14, p.811, 2015.

R. H. Andtbacka, H. L. Kaufman, F. Collichio, T. Amatruda, N. Senzer et al., Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma, J Clin Oncol, vol.33, issue.25, p.26014293, 2015.

S. T. Workenhe, G. Simmons, J. G. Pol, B. D. Lichty, W. P. Halford et al., Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy, Mol Ther, vol.22, issue.1, p.3978812, 2014.

H. L. Kaufman, F. J. Kohlhapp, and A. Zloza, Oncolytic viruses: a new class of immunotherapy drugs, Nat Rev Drug Discov, vol.14, issue.9, pp.642-62, 2015.

T. Alain, X. Lun, Y. Martineau, P. Sean, B. Pulendran et al., Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production, Proc Natl Acad Sci, vol.107, issue.4, p.2824402, 2010.

X. Lun, A. T. Zemp, F. J. Zhou, H. Rahman, M. M. Hamilton et al., Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin, Cancer Res, vol.70, issue.2, pp.598-608, 2010.

X. Fu, L. Tao, A. Rivera, and X. Zhang, Rapamycin enhances the activity of oncolytic herpes simplex virus against tumor cells that are resistant to virus replication, Int J Cancer, vol.129, issue.6, p.3133790, 2011.

B. D. Fonseca, E. M. Smith, N. Yelle, A. T. Bushell, M. Pause et al., The ever-evolving role of mTOR in translation, Semin Cell Dev Biol, vol.36, p.25263010, 2014.

W. Cao, S. Manicassamy, H. Tang, S. P. Kasturi, A. Pirani et al., Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)KmTOR-p70S6K pathway, Nat Immunol, vol.9, issue.10, p.3732485, 2008.

S. Kaur, E. Katsoulidis, and L. C. Platanias, Akt and mRNA translation by interferons, Cell Cycle, vol.7, issue.14, p.18635959, 2008.

B. Kroczynska, S. Kaur, E. Katsoulidis, B. Majchrzak-kita, A. Sassano et al., Interferon-dependent engagement of eukaryotic initiation factor 4B via S6 kinase (S6K)-and ribosomal protein S6K-mediated signals, Mol Cell Biol, vol.29, issue.10, p.2682034, 2009.

F. Wang, A. T. Szretter, K. J. Stephenson, K. Pol, J. G. Atherton et al., S6K-STING interaction regulates cytosolic DNA-mediated activation of the transcription factor IRF3, Nat Immunol, vol.17, issue.5, pp.514-536, 2016.

, PLOS Pathogens |, 2018.

S. Kaur, L. Lal, A. Sassano, B. Majchrzak-kita, M. Srikanth et al., Regulatory effects of mammalian target of rapamycin-activated pathways in type I and II interferon signaling, J Biol Chem, vol.282, issue.3, p.17114181, 2006.

R. Colina, M. Costa-mattioli, R. J. Dowling, M. Jaramillo, L. H. Tai et al., Translational control of the innate immune response through IRF-7, Nature, vol.452, issue.7185, pp.323-331, 2008.

A. Nehdi, P. Sean, I. Linares, R. Colina, M. Jaramillo et al., Deficiency in either 4E-BP1 or 4E-BP2 augments innate antiviral immune responses, PLoS One, vol.9, issue.12, p.4273997, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01198954

X. Su, Y. Yu, Y. Zhong, E. G. Giannopoulou, X. Hu et al., Interferon-gamma regulates cellular metabolism and mRNA translation to potentiate macrophage activation, Nat Immunol, vol.16, issue.8, p.4509841, 2015.

H. D. Hoang, T. E. Graber, and A. T. , Battling for Ribosomes: Translational Control at the Forefront of the Antiviral Response, J Mol Biol, vol.430, issue.14, p.29746850, 2018.

R. J. Jackson, C. U. Hellen, and T. V. Pestova, The mechanism of eukaryotic translation initiation and principles of its regulation, Nat Rev Mol Cell Biol, vol.11, issue.2, p.4461372, 2010.

A. C. Gingras, B. Raught, S. P. Gygi, A. Niedzwiecka, M. Miron et al., Hierarchical phosphorylation of the translation inhibitor 4E-BP1, Genes Dev, vol.15, issue.21, p.312813, 2001.

Y. Tsukumo, A. T. Fonseca, B. D. Nadon, R. Sonenberg, and N. , Translation control during prolonged mTORC1 inhibition mediated by 4E-BP3, Nat Commun, vol.7, p.4915159, 2016.

M. Bhat, N. Robichaud, L. Hulea, N. Sonenberg, J. Pelletier et al., Targeting the translation machinery in cancer, Nat Rev Drug Discov, vol.14, issue.4, pp.261-78, 2015.

D. Benjamin, M. Colombi, C. Moroni, and M. N. Hall, Rapamycin passes the torch: a new generation of mTOR inhibitors, Nat Rev Drug Discov, vol.10, issue.11, pp.868-80, 2011.

T. Alain, M. Morita, B. D. Fonseca, A. Yanagiya, N. Siddiqui et al., eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies, Cancer Res, vol.72, issue.24, pp.6468-76, 2012.

M. Bhat, A. Yanagiya, T. Graber, N. Razumilava, S. Bronk et al., Metformin requires 4E-BPs to induce apoptosis and repress translation of Mcl-1 in hepatocellular carcinoma cells, Oncotarget, 2017.
URL : https://hal.archives-ouvertes.fr/pasteur-01350841

, , vol.8, p.28881582, 2016.

P. Central and P. , , p.5584165

U. Chuluunbaatar, R. Roller, M. E. Feldman, S. Brown, K. M. Shokat et al., Constitutive mTORC1 activation by a herpesvirus Akt surrogate stimulates mRNA translation and viral replication, Genes Dev, vol.24, issue.23, p.21123650, 2010.

P. Central and P. , , p.2994037

N. J. Moorman and T. Shenk, Rapamycin-resistant mTORC1 kinase activity is required for herpesvirus replication, J Virol, vol.84, issue.10, p.2863801, 2010.

M. M. Stanford, M. Shaban, J. W. Barrett, S. J. Werden, P. A. Gilbert et al., Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo, Mol Ther, vol.16, issue.1, p.17998900, 2008.

X. Q. Lun, J. H. Jang, N. Tang, H. Deng, R. Head et al., Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide, Clin Cancer Res, vol.15, issue.8, pp.2777-88, 2009.

X. Q. Lun, H. Zhou, A. T. Sun, B. Wang, L. Barrett et al., Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin, Cancer Res, vol.67, issue.18, p.17875723, 2007.

R. A. Saxton and D. M. Sabatini, mTOR Signaling in Growth, Metabolism, and Disease, Cell, vol.169, issue.2, p.28388417, 2017.

C. M. Van-golen, V. P. Castle, and E. L. Feldman, IGF-I receptor activation and BCL-2 overexpression prevent early apoptotic events in human neuroblastoma, Cell Death Differ, vol.7, issue.7, pp.654-65, 2000.

, PLOS Pathogens |, 2018.

J. L. Biedler, B. A. Spengler, T. D. Chang, and R. A. Ross, Transdifferentiation of human neuroblastoma cells results in coordinate loss of neuronal and malignant properties, Prog Clin Biol Res, vol.271, pp.265-76, 1988.

J. Ursini-siegel, A. B. Rajput, H. Lu, V. Sanguin-gendreau, D. Zuo et al., Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor development, Mol Cell Biol, vol.27, issue.18, p.2099621, 2007.

K. A. Streby, J. I. Geller, M. A. Currier, P. S. Warren, J. M. Racadio et al., Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients, Clin Cancer Res, vol.23, issue.14, p.28495911, 2017.

S. Kaur, A. Sassano, B. Majchrzak-kita, D. P. Baker, B. Su et al., Regulatory effects of mTORC2 complexes in type I IFN signaling and in the generation of IFN responses, Proc Natl Acad Sci U S A, vol.109, issue.20, p.22550181, 2012.

P. Central and P. , , p.3356630

M. E. Feldman, B. Apsel, A. Uotila, R. Loewith, Z. A. Knight et al., Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2, PLoS Biol, vol.7, issue.2, 2009.

R. J. Dowling, I. Topisirovic, A. T. Bidinosti, M. Fonseca, B. D. Petroulakis et al., mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs, Science, vol.328, issue.5982, p.2893390, 2010.

V. Gandin, L. Masvidal, L. Hulea, S. P. Gravel, M. Cargnello et al., nanoCAGE reveals 5' UTR features that define specific modes of translation of functionally related MTOR-sensitive mRNAs

, Genome Res, vol.26, issue.5, p.4864462, 2016.

S. Esaki, S. D. Rabkin, R. L. Martuza, and H. Wakimoto, Transient fasting enhances replication of oncolytic herpes simplex virus in glioblastoma, Am J Cancer Res, vol.6, issue.2, p.4859661, 2016.

C. Bi, X. Zhang, T. Lu, X. Zhang, X. Wang et al., Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas, Haematologica, vol.102, issue.4, p.5395116, 2017.

A. Lazaris-karatzas, K. S. Montine, and N. Sonenberg, Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap, Nature, vol.345, issue.6275, pp.544-551, 1990.

B. A. Jacobson, A. A. Sadiq, S. Tang, J. Jay-dixon, M. R. Patel et al., Cap-dependent translational control of oncolytic measles virus infection in malignant mesothelioma, Oncotarget, vol.8, issue.38, p.5609906, 2017.

A. Yanagiya, E. Suyama, H. Adachi, Y. V. Svitkin, P. Aza-blanc et al., Translational homeostasis via the mRNA cap-binding protein, eIF4E, Mol Cell, vol.46, issue.6, p.4085128, 2012.

G. Armengol, F. Rojo, J. Castellvi, C. Iglesias, M. Cuatrecasas et al., 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications, Cancer Res, vol.67, issue.16, p.17699757, 2007.

S. T. Workenhe, T. Ketela, J. Moffat, B. P. Cuddington, and K. L. Mossman, Genome-wide lentiviral shRNA screen identifies serine/arginine-rich splicing factor 2 as a determinant of oncolytic virus activity in breast cancer cells, Oncogene, vol.35, p.26257065, 2016.

S. T. Workenhe, J. G. Pol, B. D. Lichty, D. T. Cummings, and K. L. Mossman, Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy, Cancer Immunol Res, vol.1, issue.5, pp.309-328, 2013.

J. L. Hummel, E. Safroneeva, and K. L. Mossman, The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma, Mol Ther, vol.12, issue.6, 2005.

A. Ribas, R. Dummer, I. Puzanov, A. Vanderwalde, R. Andtbacka et al., Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy, PLOS Pathogens, vol.48, issue.6, p.28886381, 2017.

D. E. Meyers, A. A. Wang, C. M. Thirukkumaran, and D. G. Morris, Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy, Front Oncol, vol.7, p.5459877, 2017.

M. Kobayashi, A. C. Wilson, M. V. Chao, and I. Mohr, Control of viral latency in neurons by axonal mTOR signaling and the 4E-BP translation repressor, Genes Dev, vol.26, issue.14, p.3404381, 2012.

M. B. Wilck, R. A. Zuckerman, and P. Astidco, Herpes simplex virus in solid organ transplantation, Am J Transplant, vol.13, p.23465005, 2013.

S. J. Russell and G. N. Barber, Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines, Cancer Cell, vol.33, issue.4, p.29634947, 2018.

M. C. Brown and M. Gromeier, MNK Controls mTORC1:Substrate Association through Regulation of TELO2 Binding with mTORC1, Cell Rep, vol.18, issue.6, p.5321627, 2017.

P. A. Geter, A. W. Ernlund, S. Bakogianni, A. Alard, R. Arju et al., Hyperactive mTOR and MNK1 phosphorylation of eIF4E confer tamoxifen resistance and estrogen independence through selective mRNA translation reprogramming, Genes Dev, vol.31, issue.22, p.5769768, 2017.

M. Morita, S. P. Gravel, V. Chenard, K. Sikstrom, L. Zheng et al., mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation, Cell Metab, vol.18, issue.5, p.24206664, 2013.

S. A. Bustin, V. Benes, J. A. Garson, J. Hellemans, J. Huggett et al., The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments, Clin Chem, vol.55, issue.4, p.19246619, 2009.

S. Taylor, M. Wakem, G. Dijkman, M. Alsarraj, and M. Nguyen, A practical approach to RT-qPCR-Publishing data that conform to the MIQE guidelines, Methods, vol.50, issue.4, p.20215014, 2010.

V. Gandin, K. Sikstrom, A. T. Morita, M. Mclaughlan, S. Larsson et al., Polysome Fractionation and Analysis of Mammalian Translatomes on a Genome-wide Scale, J Vis Exp, issue.87, 2014.